P08. Institut National de la Santé et de la Recherche Médicale, Montpellier, France
Principal Investigator: Charles Theillet

Charles Theillet, Short profile

Ph.D. 1982 in Plant Biology and moved to the cancer field during his post-doc from 1982-1986 at the NCI/NIH, Bethesda, Md USA. Back to France, gained a permanent position at the Institut National pour la Santé et la Recherche Médicale (INSERM, www.inserm.fr) in 1987 and established his research activity in Montpellier. He has been working since on molecular alterations associated to cancer development, particularly in breast and ovarian cancer for the past 20 years. He has strong interest in both basic aspects of cancer biology and translational results and benefit to the patients as end-product.
He is presently group leader and Deputy Director at IRCM (Institut de Recherche en Cancérologie de Montpellier), which is a fundamental and translational research facility located on the grounds of the Cancer Hospital of Montpellier (CRLC Val d'Aurelle).

The group of Charles Theillet has engaged in a program aiming at establishing collections of primary tumourgrafts. These tumourgrafts correspond to human primary tumours grafted freshly after surgery onto immunosuppressed mice. The team is Partner 8 in OCTIPS and contributes to the model system work package (WP4) in which it will make available the 29 ovarian cancer tumourgrafts he has established. Tumourgrafts retain histological and genetic characteristics of the primary tumour and constitute excellent models of the original cancer in the patient. They are great tools for preclinical tests and will prove central to testing drugs that will target treatment resistant ovarian cancers.

http://www.ircm.fr/document.php?pagendx=44

References
Chambon M, Orsetti B, Bascoul-Mollevi C, Berthe ML, RodriguezC , Vanessa Duong V, Gleizes M1, Thenot S, Bideau F, Theillet C, Cavailles V. Prognostic significance of TRIM24/TIF-1b gene expression in breast cancer. Am J Pathol. 178:1461-9, 2011
Tuduri S, Crabbé L, Conti C, Tourrière H, Holtgreve-Grez H, Jauch A, Pantesco V, De Vos J, Thomas A, Theillet C, Pommier Y, Tazi J, Coquelle A, Pasero P. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol. 11:1315-24, 2009.
Bertucci F, Orsetti B, Negre V, Finetti P, Rouge C, Ahomadegbe JC, Bibeau F, Mathieu MC, Treilleux I, Jacquemier J, Ursule L, Martinec A, Wang Q, Benard J, Puisieux A, Birnbaum D, Theillet C. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene. 27:5359-72, 2008.
Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM. A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. Clin Cancer Res. 14:1744-52, 2008
Côme C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res, 12:5395-402, 2006.